Jazz Pharmaceuticals

Jazz Pharmaceuticals (JAZZ) stock is currently trading at $207.83 per share on the NASDAQ exchange. This represents a daily gain of +1.35% ($2.77) from the previous closing price of $205.06. Over the past 52 weeks, JAZZ has traded between a low of $128.80 and a high of $266.38, placing the current price at approximately -22% from its annual high. The stock has a market capitalization of $13.44B, making it one of the larger cannabis companies tracked by Cannabismarketcap. Jazz Pharmaceuticals operates in the Biotech sector, classified under "PHARMACEUTICAL PREPARATIONS", serving the broader cannabis industry.

Jazz Pharmaceuticals (JAZZ) has a current market capitalization of $13.44B, calculated by multiplying its 64.9M shares outstanding by the current stock price of $207.83. Market capitalization is a key measure of a company's total equity value as perceived by the public market, and it places Jazz Pharmaceuticals among the large-cap cannabis companies tracked on Cannabismarketcap. For context, the enterprise value (market cap plus debt minus cash) stands at $16.17B, which accounts for the company's balance sheet structure. Investors often use market cap alongside revenue and profitability metrics to assess relative valuation within the cannabis sector.

Jazz Pharmaceuticals (JAZZ) reports trailing twelve month (TTM) revenue of $4.60B, reflecting the total sales generated by the company over the most recent four quarters. Revenue has changed +12.59% year-over-year, indicating growth momentum relative to the prior period. The current price-to-sales ratio is 2.92x, which means investors are paying $2.92 for every $1 of annual revenue — a moderate valuation in the context of the cannabis sector. Revenue is one of the most closely watched metrics for cannabis companies, as many are still scaling operations in a rapidly evolving regulatory environment. View the full income statement and quarterly revenue breakdown on Cannabismarketcap for detailed trend analysis.

Jazz Pharmaceuticals currently employs approximately 2,890 people across its operations. As a cannabis biotech company headquartered in the United States, its workforce supports activities spanning pharmaceutical preparations and related business functions. Based on trailing twelve month revenue of $4.60B, this equates to approximately $1.6M in revenue per employee, which is a useful efficiency metric for comparing operational productivity across cannabis companies. Employee count is an important indicator of a company's operational scale and its capacity for growth in an industry that remains highly labor-intensive due to regulatory requirements.

Jazz Pharmaceuticals trades under the ticker symbol JAZZ on the NASDAQ exchange, and the stock is denominated in US dollars (USD). Shares can typically be purchased through most standard brokerage accounts. The company has been publicly listed since 2007-06-01, giving it a track record in the public markets that investors can analyze for long-term trends. The stock sees average daily trading volume of approximately 773.6K shares, which is an important consideration for liquidity and the ability to enter or exit positions without significant price impact.

Jazz Pharmaceuticals (JAZZ) has traded between a 52-week low of $128.80 and a 52-week high of $266.38, with the current price of $207.83 sitting approximately -22% from the annual high. This range represents a spread of $137.57 (107% from low to high), which reflects the volatility the stock has experienced over the past year. The 52-week range is a commonly used technical indicator that helps investors understand whether a stock is trading near the top or bottom of its recent range, and it can inform decisions about entry and exit points. Cannabis stocks in general tend to exhibit higher volatility than broader market indices due to evolving regulations and market sentiment.

Jazz Pharmaceuticals (JAZZ) holds $1.62B in cash and equivalents on its balance sheet, set against $4.35B in total debt. This gives the company a net debt position of $2.73B. Balance sheet strength is especially important in the cannabis industry, where companies often face limited access to traditional banking and capital markets. Investors should track these metrics over time on Cannabismarketcap to identify trends in cash consumption and debt management.

Jazz Pharmaceuticals (JAZZ) currently has 64.9M shares outstanding, which when multiplied by the current stock price of $207.83 gives the company its market capitalization of $13.44B. Share count is important because all per-share metrics (earnings per share, book value per share, etc.) are directly impacted by changes in shares outstanding. Cannabis companies frequently issue new shares to raise capital, so monitoring dilution trends on Cannabismarketcap is recommended for long-term investors.